An interventional study of Increasing the pacemaker lower rate and Standard setting in Cardiac Amyloidosis and Pacemaker, sponsored by Region Skane. Not yet recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Region Skane · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Amyloid Neuropathies, Familial with a site in Sweden — 3 open to participants now, 3 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · Sweden.
Among the 13 studies in Amyloid Neuropathies, Familial with a site in Sweden, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is the only one with no phase, and was the 13th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →3 of the 13 studies in Amyloid Neuropathies, Familial with a site in Sweden are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Sweden, United States, Argentina and 21 more countries
Ages 18–75
Intellia Therapeutics · Sites in Sweden, France, New Zealand and 1 more country
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 9
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 168 across the 12 interventional studies, 72 across the 1 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 6 most frequent:
Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Region Skane has 1 study filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Amyloid Neuropathies, Familial with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more dependent on having an adequate heart rate. Many develop conduction problems and need a pacemaker. In a related condition, heart failure with preserved ejection fraction, setting a higher pacemaker rate improved patients' quality of life. It is not known if the same benefits apply to amyloidosis. This study will test whether raising the pacemaker rate improves well-being and daily function in affected patients.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of restrictive cardiomyopathy, characterized by reduced ventricular compliance, low stroke volume, and marked dependence on heart rate for maintenance of cardiac output. Conduction disease is common in ATTR-CM, and a substantial proportion of patients require permanent pacemaker implantation.
Although disease-modifying therapy can slow disease progression, evidence guiding optimization of pacemaker therapy in ATTR-CM is lacking. In heart failure with preserved ejection fraction, a condition also characterized by reduced ventricular compliance, increased pacemaker lower rate settings have been shown to improve functional capacity and quality of life. However, patients with cardiac amyloidosis were excluded from these studies. Consequently, current practice in ATTR-CM relies largely on extrapolation and expert opinion.
In this randomized multicenter 2×2 crossover trial, we aim to determine whether a higher pacemaker lower rate (80 bpm) improves health-related quality of life (QoL) and functional capacity in patients with ATTR-CM compared with the standard setting of 60 bpm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Increasing the pacemaker lower rate
Device: Standard setting
Increasing the pacemaker lower rate from 60 to 80 bpm
Lower rate setting of 60 bpm
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
The MLHFQ is a validated patient-reported outcome assessing heart failure-related quality of life. It consists of 21 items scored 0-5, yielding a total score range of 0-105. Higher scores indicate worse quality of life. MLHFQ is collected at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
Distance walked during the 6-Minute Walk Test (6MWT)
The 6-Minute Walk Test measures the distance walked in meters during six minutes on a flat, hard surface. The distance walked ranges from 0 meters upward, with higher distances indicating better functional capacity. The 6MWT is performed at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
Levels of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)
NT-proBNP is a circulating biomarker of myocardial wall stress and heart failure severity. It is measured in pg/mL. Higher concentrations indicate worse cardiac function. NT-proBNP is assessed at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
New York Heart Association (NYHA) Functional Class
NYHA functional class is a measure of heart failure severity ranging from Class I to Class IV, with higher class indicating worse functional status. NYHA class is assessed at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
National Amyloidosis Centre (NAC) Stage
National Amyloidosis Centre (NAC) stage is a prognostic staging system for transthyretin cardiac amyloidosis based on cardiac biomarkers. It is categorized as Stage I, II, or III, with higher stage indicating more advanced disease. NAC stage is assessed at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
Number of participants with hospitalization or urgent outpatient visit for atrial fibrillation
This outcome captures atrial fibrillation-related hospitalizations or urgent outpatient visits occurring during each treatment period.
Time frame: During each treatment period (approximately 3 months per period)
Atrial fibrillation burden assessed by implanted pacemaker
Atrial fibrillation (AF) burden is defined as the percentage of time spent in atrial fibrillation, as recorded by the implanted pacemaker's arrhythmia detection algorithms. Higher values indicate greater arrhythmia burden.
Time frame: During each treatment period (approximately 3 months per period)
Physical activity level assessed by implanted pacemaker
Physical activity is assessed using the implanted pacemaker's built-in activity sensor. Higher values indicate greater physical activity.
Time frame: During each treatment period (approximately 3 months per period)
Levels of High-Sensitivity Cardiac Troponin (hs-cTn)
High-sensitivity cardiac troponin (hs-cTn) is a biomarker of myocardial injury. It is measured in ng/L in plasma. Higher concentrations indicate greater myocardial injury. hs-cTn is assessed at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
Number of participants with hospitalization or urgent outpatient visit for heart failure
This outcome captures heart failure-related hospitalizations or urgent outpatient visits occurring during each treatment period.
Time frame: During each treatment period (approximately 3 months per period)
Daily loop diuretic dose
Daily loop diuretic dose is recorded as milligrams per day. Higher doses indicate greater diuretic requirement. Loop diuretic dosing is assessed at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
Number of participants with cardiac death
Cardiac death is defined as death resulting from cardiovascular causes, including heart failure, arrhythmia, or sudden cardiac death, as assessed by the site investigator.
Time frame: Through study completion (up to approximately 7 months)
Left Ventricular Ejection Fraction (LVEF)
Left ventricular ejection fraction (LVEF) is expressed as a percentage (%). Higher values indicate better systolic function. LVEF is assessed by echocardiography at Visits 1-4.
Time frame: End of each treatment period (Visit 2 at approximately 3 months and Visit 4 at approximately 7 months)
Start is estimated for Feb 2026; primary completion for Dec 2027, 22 months later.
Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →